The authors acknowledge the support by the National Basic Research Program of China(Nos.2020YFA0710700 and 2018YFA0208900);the National Natural Science Foundation of China(No.31470968).
The combinational chemo-immunotherapy as a novel treatment strategy has been widely studied and applied in clinic to enhance antitumor therapeutic efficacy and relieve side effects.RNA interference(RNAi)targeting PD-L...
This work was supported by National Key Basic Research Program of China(No.2015CB554000).
Aim:Immune checkpoint inhibitors(ICIs)are proven to be an effective way to treat the disease of hematologic malignancies.But there is still plenty of uncertainty about the effectiveness of ICIs on hepatocellular carci...
This work was supported by the Ministry of Science and Technology of China (973 program: 2013CB531502 and 2014CB542503), the National Natural Science Foundation of Chi- na (NSFC; 31390432 and 31500722), Grand S&T project of China Health and Family Planning Commission (2013ZX10004608-002 and 2016ZX10004201-009), the Strategic Priority Research Pro- gram of the Chinese Academy of Sciences (CAS; XDB08020100). We thank the staff of BL17U beamline at Shanghai Synchrotron Radiation Facility for assistance with data collection. YS is sup-ported by the Excellent Young Scientist Program of CAS and the Youth Innovation Promotion Association of CAS (2015078). GFG is supported partly as a leading principal investigator of the NSFC Innovative Research Group (81321063).
Monoclonal antibodies (mAbs) blocking immune checkpoint molecules, especially programmed cell death l (PD-1) and its ligands programmed cell death 1 ligand 1 (PD-L1) and ligand 2 (PD-L2), are currently been in...